{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:22:14Z","timestamp":1765290134374,"version":"3.46.0"},"reference-count":35,"publisher":"Aboutscience Srl","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["dti"],"abstract":"<jats:p>Introduction: Atypical hemolytic uremic syndrome (aHUS) is a potentially life-threatening condition associatedwith poor clinical outcomes if not treated adequately. Eculizumab has become the standard of care, whereasravulizumab, a second-generation, high-affinity complement C5 inhibitor, demonstrates comparable efficacyin improving renal function, hematological markers, and dialysis rates. In addition, ravulizumab offers practicaladvantages, including a longer dosing interval and immediate, complete, and sustained inhibition of free C5,making it a valuable therapeutic option.Methods: Given the limited real-world experience with ravulizumab, we present a case series of six treatmentna\u00efveaHUS patients who received ravulizumab as first-line therapy.Results: These cases include one pregnancy-related aHUS, one postpartum case, one related to a urinary tractinfection, one associated with hypertension, one with a pneumonia-related trigger, and one kidney transplantpatient with a prior verotoxin-producing E. coli infection. Altogether, these cases illustrate the challenges in diagnosing aHUS. The choice to administer ravulizumab as first-line treatment was sometimes made in the presence of a clear clinical suspicion, even when not all minor criteria seemed to confirm the diagnosis. In most patients, renal function improved rapidly after ravulizumab administration, followed by recovery of hematological parameters, which were stable in the longer term. As improvements remained sustained over time, the possibility of discontinuing ravulizumab can be evaluated on a case-by-case basis.Conclusion: These cases highlight the importance of early diagnosis, prompt intervention, and multidisciplinarycare in managing aHUS. Ravulizumab as first-line therapy proved effective and well-tolerated, with sustainedclinical improvements observed across diverse real-world scenarios.<\/jats:p>","DOI":"10.33393\/dti.2025.3616","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:17:58Z","timestamp":1765289878000},"page":"99-107","source":"Crossref","is-referenced-by-count":0,"title":["Ravulizumab in treatment-na\u00efve patients with atypical hemolytic uremic syndrome: a real-world case series"],"prefix":"10.33393","volume":"19","author":[{"given":"Livia Maria","family":"Sorrentino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candida","family":"Iacuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Sciri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Zacchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariarosaria","family":"Iannuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Marotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5108-7385","authenticated-orcid":false,"given":"Piercarla","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Taglioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5638-0837","authenticated-orcid":false,"given":"Floriana","family":"Secondulfo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Palazzetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco","family":"Baccaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18642","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"18119","doi-asserted-by":"crossref","unstructured":"Raina R, Krishnappa V, Blaha T, et al. Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019;23(1):4-21. https:\/\/doi.org\/10.1111\/1744-9987.12763 PMID:30294946","DOI":"10.1111\/1744-9987.12763"},{"key":"18120","doi-asserted-by":"crossref","unstructured":"Yoshida Y, Kato H, Ikeda Y, et al. Pathogenesis of atypical hemolytic uremic syndrome. J Atheroscler Thromb. 2019;26(2):99-110. https:\/\/doi.org\/10.5551\/jat.RV17026 PMID:30393246","DOI":"10.5551\/jat.RV17026"},{"key":"18121","doi-asserted-by":"crossref","unstructured":"Loirat C, Fr\u00e9meaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6(1):60. https:\/\/doi.org\/10.1186\/1750-1172-6-60 PMID:21902819","DOI":"10.1186\/1750-1172-6-60"},{"key":"18122","doi-asserted-by":"crossref","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554-562. https:\/\/doi.org\/10.2215\/CJN.04760512 PMID:23307876","DOI":"10.2215\/CJN.04760512"},{"key":"18123","doi-asserted-by":"crossref","unstructured":"Petr V, Thurman JM. The role of complement in kidney disease. Nat Rev Nephrol. 2023;19(12):771-787. https:\/\/doi.org\/10.1038\/s41581-023-00766-1 PMID:37735215","DOI":"10.1038\/s41581-023-00766-1"},{"key":"18124","doi-asserted-by":"crossref","unstructured":"Vivarelli M, Barratt J, Beck LH Jr, et al.. The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2024;106(3):369-391. https:\/\/doi.org\/10.1016\/j.kint.2024.05.015 PMID:38844295","DOI":"10.1016\/j.kint.2024.05.015"},{"key":"18125","doi-asserted-by":"crossref","unstructured":"Stea ED, D\u2019Ettorre G, Mitrotti A, et al. The complement system in the pathogenesis and progression of kidney diseases: what doesn't kill you makes you older. Eur J Intern Med. 2024;124:22-31. https:\/\/doi.org\/10.1016\/j.ejim.2024.02.015 PMID:38461065","DOI":"10.1016\/j.ejim.2024.02.015"},{"key":"18126","doi-asserted-by":"crossref","unstructured":"Duval A, Fr\u00e9meaux-Bacchi V. Complement biology for hematologists. Am J Hematol. 2023;98(S4)(suppl 4):S5-S19. https:\/\/doi.org\/10.1002\/ajh.26855 PMID:36688486","DOI":"10.1002\/ajh.26855"},{"key":"18127","doi-asserted-by":"crossref","unstructured":"Licht C, Al-Dakkak I, Anokhina K, et al. Characterization of patients with aHUS and associated triggers or clinical conditions: a global aHUS registry analysis. Nephrology (Carlton). 2024;29(8):519-527. https:\/\/doi.org\/10.1111\/nep.14304 PMID:38604995","DOI":"10.1111\/nep.14304"},{"key":"18128","doi-asserted-by":"crossref","unstructured":"Meena P, Gala R, Das RR, et al. Kidney and pregnancy outcomes in pregnancy-associated atypical hemolytic uremic syndrome: a systematic review and meta-analysis. Medicine (Baltimore). 2025;104(5):e41403. https:\/\/doi.org\/10.1097\/MD.0000000000041403 PMID:39889176","DOI":"10.1097\/MD.0000000000041403"},{"key":"18129","unstructured":"Laurence J, Haller H, Mannucci PM, et al. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin Adv Hematol Oncol. 2016;14 Suppl 11(11):2-15. PMID: 27930620"},{"key":"18130","doi-asserted-by":"crossref","unstructured":"West EE, Woodruff T, Fr\u00e9meaux-Bacchi V, et al. Complement in human disease: approved and up-and-coming therapeutics. Lancet. 2024;403(10424):392-405. https:\/\/doi.org\/10.1016\/S0140-6736(23)01524-6 PMID:37979593","DOI":"10.1016\/S0140-6736(23)01524-6"},{"key":"18131","doi-asserted-by":"crossref","unstructured":"Bouwman HB, Guchelaar HJ. The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms. Drug Discov Today. 2024;29(9):104134. https:\/\/doi.org\/10.1016\/j.drudis.2024.104134 PMID:39111540","DOI":"10.1016\/j.drudis.2024.104134"},{"key":"18132","doi-asserted-by":"crossref","unstructured":"McKeage K. Ravulizumab. First global approval. Drugs. 2019;79(3):347-352. https:\/\/doi.org\/10.1007\/s40265-019-01068-2 PMID:30767127","DOI":"10.1007\/s40265-019-01068-2"},{"key":"18133","doi-asserted-by":"crossref","unstructured":"Shahid K, Qayyum S. Eculizumab versus ravulizumab for the treatment of atypical hemolytic uremic syndrome: a systematic review. Cureus. 2023;15(9):e46185. https:\/\/doi.org\/10.7759\/cureus.46185 PMID:37905269","DOI":"10.7759\/cureus.46185"},{"key":"18134","doi-asserted-by":"crossref","unstructured":"Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530-539. https:\/\/doi.org\/10.1182\/blood-2018-09-876136 PMID:30510080","DOI":"10.1182\/blood-2018-09-876136"},{"key":"18135","doi-asserted-by":"crossref","unstructured":"Legendre C, Rebecca-Sberro-Soussan, Zuber J. Ravulizumab for the treatment of aHUS in adults: improving quality of life. Kidney Int Rep. 2021;6(6):1489-1491. https:\/\/doi.org\/10.1016\/j.ekir.2021.04.036 PMID:34169186","DOI":"10.1016\/j.ekir.2021.04.036"},{"key":"18136","doi-asserted-by":"crossref","unstructured":"Mauch TJ, Chladek MR, Cataland S, et al. Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome. J Comp Eff Res. 2023;12(9):e230036. https:\/\/doi.org\/10.57264\/cer-2023-0036 PMID:37515502","DOI":"10.57264\/cer-2023-0036"},{"key":"18137","doi-asserted-by":"crossref","unstructured":"Fakhouri F, Schwotzer N, Fr\u00e9meaux-Bacchi V. How I diagnose and treat atypical hemolytic uremic syndrome. Blood. 2023;141(9):984-995. https:\/\/doi.org\/10.1182\/blood.2022017860 PMID:36322940","DOI":"10.1182\/blood.2022017860"},{"key":"18138","doi-asserted-by":"crossref","unstructured":"Rondeau E, Scully M, Ariceta G, et al.; 311 Study Group. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment. Kidney Int. 2020;97(6):1287-1296. https:\/\/doi.org\/10.1016\/j.kint.2020.01.035 PMID:32299680","DOI":"10.1016\/j.kint.2020.01.035"},{"key":"18139","doi-asserted-by":"crossref","unstructured":"Sch\u00f6nfelder K, K\u00fchne L, Schulte-Kemna L, et al. Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS- real-world data. BMC Nephrol. 2024;25(1):202. https:\/\/doi.org\/10.1186\/s12882-024-03638-3 PMID:38898427","DOI":"10.1186\/s12882-024-03638-3"},{"key":"18140","doi-asserted-by":"crossref","unstructured":"Schaefer F, Al-Dakkak I, Anokhina K, et al. Global aHUS registry analysis of patients switching to ravulizumab from eculizumab. Kidney Int Rep. 2024;9(9):2648-2656. https:\/\/doi.org\/10.1016\/j.ekir.2024.06.020 PMID:39291212","DOI":"10.1016\/j.ekir.2024.06.020"},{"key":"18141","unstructured":"Ultomiris. Riassunto delle caratteristiche del prodotto. Online https:\/\/ec.europa.eu\/health\/documents\/community-register\/2023\/20230531159289\/anx_159289_it.pdf (Accessed July 2025)"},{"key":"18142","doi-asserted-by":"crossref","unstructured":"\u00c1vila A, Cao M, Espinosa M, et al. Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults. Front Med (Lausanne). 2023;10:1264310. https:\/\/doi.org\/10.3389\/fmed.2023.1264310 PMID:38105887","DOI":"10.3389\/fmed.2023.1264310"},{"key":"18143","doi-asserted-by":"crossref","unstructured":"Cadet B, Meshoyrer D, Kim Z. Atypical hemolytic uremic syndrome: when pregnancy leads to lifelong dialysis: a case report and literature review. Cardiovasc Endocrinol Metab. 2021;10(4):225-230. https:\/\/doi.org\/10.1097\/XCE.0000000000000247 PMID:34765894","DOI":"10.1097\/XCE.0000000000000247"},{"key":"18144","doi-asserted-by":"crossref","unstructured":"Mirza M, Sadiq N, Aye C. Pregnancy-associated atypical hemolytic uremic syndrome and life-long kidney failure. Cureus. 2022;14(6):e25655. https:\/\/doi.org\/10.7759\/cureus.25655 PMID:35800199","DOI":"10.7759\/cureus.25655"},{"key":"18145","doi-asserted-by":"crossref","unstructured":"Fakhouri F, Scully M, Prov\u00f4t F, et al. Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood. 2020;136(19):2103-2117. https:\/\/doi.org\/10.1182\/blood.2020005221 PMID:32808006","DOI":"10.1182\/blood.2020005221"},{"key":"18146","doi-asserted-by":"crossref","unstructured":"Che M, Moran SM, Smith RJ, et al. A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome\/complement-mediated thrombotic microangiopathy. Kidney Int. 2024;105(5):960-970. https:\/\/doi.org\/10.1016\/j.kint.2023.12.021 PMID:38408703","DOI":"10.1016\/j.kint.2023.12.021"},{"key":"18147","doi-asserted-by":"crossref","unstructured":"Fakhouri F, Scully M, Ardissino G, et al. Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis. J Nephrol. 2021;34(5):1581-1590. https:\/\/doi.org\/10.1007\/s40620-021-01025-x PMID:33826112","DOI":"10.1007\/s40620-021-01025-x"},{"key":"18148","doi-asserted-by":"crossref","unstructured":"Rondeau E, Ardissino G, Caby-Tosi MP, et al.; Global aHUS Registry. Pregnancy in women with atypical hemolytic uremic syndrome. Nephron J. 2022;146(1):1-10. https:\/\/doi.org\/10.1159\/000518171 PMID:34515154","DOI":"10.1159\/000518171"},{"key":"18149","doi-asserted-by":"crossref","unstructured":"Wijnsma KL, Duineveld C, Volokhina EB, et al. Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. Nephrol Dial Transplant. 2018;33(4):635-645. https:\/\/doi.org\/10.1093\/ndt\/gfx196 PMID:29106598","DOI":"10.1093\/ndt\/gfx196"},{"key":"18150","doi-asserted-by":"crossref","unstructured":"Ardissino G, Testa S, Possenti I, et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis. 2014;64(4):633-637. https:\/\/doi.org\/10.1053\/j.ajkd.2014.01.434 PMID:24656451","DOI":"10.1053\/j.ajkd.2014.01.434"},{"key":"18151","doi-asserted-by":"crossref","unstructured":"Macia M, de Alvaro Moreno F, Dutt T, et al. Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J. 2017;10(3):310-319. https:\/\/doi.org\/10.1093\/ckj\/sfw115 PMID:28621343","DOI":"10.1093\/ckj\/sfw115"},{"key":"18152","unstructured":"Laurence J. Defining treatment duration in atypical hemolytic uremic syndrome in adults: a clinical and pathological approach. Clin Adv Hematol Oncol. 2020;18(4):221-230. PMID:32628650"},{"key":"18153","doi-asserted-by":"crossref","unstructured":"Yerigeri K, Kadatane S, Mongan K, et al. Atypical hemolytic-uremic syndrome: genetic basis, clinical manifestations, and a multidisciplinary approach to management. J Multidiscip Healthc. 2023;16:2233-2249. https:\/\/doi.org\/10.2147\/JMDH.S245620 PMID:37560408","DOI":"10.2147\/JMDH.S245620"}],"container-title":["Drug Target Insights"],"original-title":[],"link":[{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/dti\/article\/download\/3616\/4161","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/dti\/article\/download\/3616\/4162","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/dti\/article\/download\/3616\/4162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:18:09Z","timestamp":1765289889000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/dti\/article\/view\/3616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,13]]}},"URL":"https:\/\/doi.org\/10.33393\/dti.2025.3616","relation":{},"ISSN":["1177-3928"],"issn-type":[{"value":"1177-3928","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]}}}